{"name":"Krystal Biotech, Inc.","slug":"krystal-biotech","ticker":"KRYS","exchange":"NASDAQ","domain":"krystalbio.com","description":"Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotec","hq":"Pittsburgh, PA","founded":0,"employees":"295","ceo":"","sector":"Biotech — Gene Therapy","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":313.32,"stockChange":0.74,"stockChangePercent":0.24,"marketCap":"$9.2B","metrics":{"revenue":417304000,"revenueGrowth":31.9,"grossMargin":94.2,"rdSpend":0,"netIncome":225030000,"cash":823404992,"dividendYield":0,"peRatio":41.9,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"KB105","genericName":"KB105","slug":"kb105","indication":"Other","status":"phase_2"},{"name":"Topical Beremagene Geperpavec","genericName":"Topical Beremagene Geperpavec","slug":"topical-beremagene-geperpavec","indication":"Dystrophic epidermolysis bullosa","status":"phase_3"},{"name":"KB301","genericName":"KB301","slug":"kb301","indication":"Other","status":"phase_1"},{"name":"KB803","genericName":"KB803","slug":"kb803","indication":"Recessive dystrophic epidermolysis bullosa (RDEB)","status":"phase_3"}]}],"pipeline":[{"name":"KB105","genericName":"KB105","slug":"kb105","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Topical Beremagene Geperpavec","genericName":"Topical Beremagene Geperpavec","slug":"topical-beremagene-geperpavec","phase":"phase_3","mechanism":"Beremagene geperpavec is a gene therapy that uses a viral vector to deliver a gene to the skin, which then produces a protein to treat the condition.","indications":["Dystrophic epidermolysis bullosa"],"catalyst":""},{"name":"KB301","genericName":"KB301","slug":"kb301","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"KB803","genericName":"KB803","slug":"kb803","phase":"phase_3","mechanism":"KB803 is a gene therapy that delivers a functional COL7A1 gene to restore type VII collagen production in patients with recessive dystrophic epidermolysis bullosa.","indications":["Recessive dystrophic epidermolysis bullosa (RDEB)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":1,"phase_3":2,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":389130000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":389130000},{"period":"2024-12-31","value":290515000},{"period":"2023-12-31","value":50699000},{"period":"2022-12-31","value":0}],"grossProfit":366081000,"grossProfitHistory":[{"period":"2025-12-31","value":366081000},{"period":"2024-12-31","value":270454000},{"period":"2023-12-31","value":47605000},{"period":"2022-12-31","value":0}],"rdSpend":58045000,"rdSpendHistory":[{"period":"2025-12-31","value":58045000},{"period":"2024-12-31","value":53580000},{"period":"2023-12-31","value":46433000},{"period":"2022-12-31","value":42461000}],"sgaSpend":146741000,"operatingIncome":161295000,"operatingIncomeHistory":[{"period":"2025-12-31","value":161295000},{"period":"2024-12-31","value":103248000},{"period":"2023-12-31","value":-97117000},{"period":"2022-12-31","value":-120196000}],"netIncome":204831000,"netIncomeHistory":[{"period":"2025-12-31","value":204831000},{"period":"2024-12-31","value":89159000},{"period":"2023-12-31","value":10932000},{"period":"2022-12-31","value":-139975000}],"eps":6.84,"epsHistory":[{"period":"2025-12-31","value":6.84},{"period":"2024-12-31","value":3},{"period":"2023-12-31","value":0.39},{"period":"2022-12-31","value":-5.49}],"cash":496304000,"cashHistory":[{"period":"2025-12-31","value":496304000},{"period":"2024-12-31","value":344865000},{"period":"2023-12-31","value":358328000},{"period":"2022-12-31","value":161900000}],"totalAssets":1333794000,"totalLiabilities":114234000,"totalDebt":9339000,"equity":1219560000,"operatingCashflow":200865000,"operatingCashflowHistory":[{"period":"2025-12-31","value":200865000},{"period":"2024-12-31","value":123420000},{"period":"2023-12-31","value":-88804000},{"period":"2022-12-31","value":-100569000}],"capex":-11951000,"capexHistory":[{"period":"2025-12-31","value":-11951000},{"period":"2024-12-31","value":-4238000},{"period":"2023-12-31","value":-11799000},{"period":"2022-12-31","value":-52979000}],"freeCashflow":188914000,"dividendsPaid":null,"buybacks":null,"employees":295,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":41014000,"ebit":53689000,"ebitda":55415000,"period":"2026-03-31","revenue":116357000,"epsBasic":1.91,"netIncome":55932000,"rdExpense":15331000,"epsDiluted":1.83,"grossProfit":110034000,"operatingIncome":53689000},{"sga":41449000,"ebit":44270000,"ebitda":46032000,"period":"2025-12-31","revenue":107105000,"epsBasic":1.77,"netIncome":51400000,"rdExpense":14794000,"epsDiluted":1.7,"grossProfit":100513000,"operatingIncome":44270000},{"sga":37578000,"ebit":41374000,"ebitda":42986000,"period":"2025-09-30","revenue":97800000,"epsBasic":2.74,"netIncome":79365000,"rdExpense":14585000,"epsDiluted":2.66,"grossProfit":93537000,"operatingIncome":41374000},{"sga":35160000,"ebit":39307000,"ebitda":40850000,"period":"2025-06-30","revenue":96042000,"epsBasic":1.33,"netIncome":38333000,"rdExpense":14410000,"epsDiluted":1.29,"grossProfit":88877000,"operatingIncome":39307000},{"sga":32647000,"ebit":36252000,"ebitda":37886000,"period":"2025-03-31","revenue":88183000,"epsBasic":1.24,"netIncome":35733000,"rdExpense":14256000,"epsDiluted":1.2,"grossProfit":83155000,"operatingIncome":36252000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":313.32,"previousClose":312.58,"fiftyTwoWeekHigh":319.48,"fiftyTwoWeekLow":122.8,"fiftyTwoWeekRange":"122.8 - 319.48","fiftyDayAverage":266.79,"twoHundredDayAverage":223.72,"beta":0.49,"enterpriseValue":8400488960,"forwardPE":31.1,"priceToBook":7.5,"priceToSales":22.13,"enterpriseToRevenue":20.13,"enterpriseToEbitda":46.55,"pegRatio":0,"ebitda":180468000,"ebitdaMargin":43.2,"freeCashflow":137491504,"operatingCashflow":250278000,"totalDebt":9112000,"debtToEquity":0.7,"currentRatio":9.46,"returnOnAssets":9,"returnOnEquity":19.9,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":9,"targetMeanPrice":318.22,"targetHighPrice":399,"targetLowPrice":241,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":11.1,"institutionHeldPercent":99.9,"sharesOutstanding":29479756,"floatShares":23369782,"sharesShort":3095771,"shortRatio":12.24,"shortPercentOfFloat":10.5,"epsTrailing":7.47,"epsForward":10.08,"revenuePerShare":14.36,"bookValue":41.78,"officers":[{"age":60,"name":"Mr. Krish S. Krishnan M.B.A., M.S.","title":"Founder, Chairman, President & CEO"},{"age":60,"name":"Ms. Suma M. Krishnan","title":"Founder, President of R&D and Director"},{"age":43,"name":"Ms. Kathryn A. Romano CPA","title":"Executive VP & Chief Accounting Officer"},{"age":51,"name":"Mr. John C. Thomas","title":"EVP, General Counsel & Corporate Secretary"},{"age":null,"name":"Mr. John  Karakkal","title":"Vice President of North American Sales & Marketing"},{"age":null,"name":"Dr. Stephane  Paquette Ph.D.","title":"Senior Vice President of Corporate Development"},{"age":null,"name":"Mr. Josh  Suskin","title":"Senior Director & Head of US Human Resources"},{"age":50,"name":"Mr. Laurent  Goux","title":"Executive VP & Head of International"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.krystalbio.com","phone":"412 586 5830"}}